Jazz Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Jazz Pharmaceuticals generated cash of $1,092,007,000, which is less than the previous year. Cash used in financing activities reached the amount of -$305,254,000 last year. Net change in cash is therefore $624,828,000.
Cash Flow
| 2014 | 405.76M | -1.06B | 712.87M |
|---|---|---|---|
| 2015 | 531.94M | -2.25M | -214.32M |
| 2016 | 590.53M | -1.74B | 540.98M |
| 2017 | 693.08M | -268.95M | -409.11M |
| 2018 | 798.90M | -394.48M | -479.13M |
| 2019 | 776.40M | -155.3M | -293.74M |
| 2020 | 899.64M | -1.00B | 528.07M |
| 2021 | 778.50M | -5.21B | 3.97B |
| 2022 | 1.27B | -446.23M | -529.49M |
| 2023 | 1.09B | -163.06M | -305.25M |
JAZZ Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 881.48M | 591.44M | 1.05B | 637.34M | 309.62M | 386.03M | 365.96M | 988.78M | 684.04M | 636.50M |
Operating activities | ||||||||||
Net income | 414.83M | -224.06M | -329.66M | 238.61M | 523.36M | 447.09M | 487.84M | 396.83M | 329.53M | 57.32M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 638.69M | 629.47M | 552.48M | 278.25M | 370.15M | 216.73M | 165.15M | 113.78M | 108.05M | 133.68M |
Stock-based compensation expense | 226.84M | 221.99M | 189.00M | 120.99M | 110.56M | 102.44M | 106.9M | 98.77M | 91.55M | 69.63M |
| Deferred income tax benefit | 226.84M | 221.99M | 189.00M | 120.99M | 110.56M | 102.44M | 106.9M | 98.77M | 91.55M | 69.63M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 0 | -90.13M | -92.73M | -38.64M | -92.32M | -40.13M | 12.27M | -25.60M | -24.84M | -55.04M |
Inventories | 0 | -49.64M | -48.86M | -30.53M | -32.79M | -18.51M | -8.66M | -17.02M | 6.27M | -7.63M |
Accounts payable | 9.60M | -11.22M | 57.02M | -18.93M | 4.77M | 17.04M | 214K | 361K | -2.28M | -37.96M |
Cash generated by operating activities | 1.09B | 1.27B | 778.50M | 899.64M | 776.40M | 798.90M | 693.08M | 590.53M | 531.94M | 405.76M |
Investing activities | ||||||||||
Purchases Of Investments | -390.1M | -61.03M | -26.81M | -2.39B | -917.1M | -1.16B | -385M | -65.27M | 0 | 0 |
Investments In Property Plant And Equipment | -23.96M | -498.19M | -45.53M | -379.25M | -182.33M | -131.47M | -113.95M | -181.58M | -35.95M | -238.97M |
Acquisitions Net | 0 | 53M | -6.23B | -364.25M | -142.2M | 111.1M | 85M | -1.50B | 33.70M | -828.67M |
Cash generated by investing activities | -163.06M | -446.23M | -5.21B | -1.00B | -155.3M | -394.48M | -268.95M | -1.74B | -2.25M | -1.06B |
Financing activities | ||||||||||
Common Stock Issued | 0 | 0 | 135.26M | 99.68M | 0 | 93.33M | 0 | 24.17M | 0 | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | -269.76M | -54K | -35.60M | -146.53M | -301.45M | -523.67M | -98.79M | -278.29M | -61.55M | -42.21M |
Repayments of term debt | -31M | -582.01M | -1.32B | -889.57M | -33.38M | -25.71M | -326.70M | -178.30M | -167.11M | -309.52M |
Cash used in financing activities | -305.25M | -529.49M | 3.97B | 528.07M | -293.74M | -479.13M | -409.11M | 540.98M | -214.32M | 712.87M |
Net Change In Cash | 624.82M | 290.03M | -466.32M | 420.42M | 327.72M | -76.41M | 20.07M | -622.82M | 304.74M | 47.53M |
Cash at end of period | 1.50B | 881.48M | 591.44M | 1.05B | 637.34M | 309.62M | 386.03M | 365.96M | 988.78M | 684.04M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |